The commercialization of generic equivalents of Lanthanum Carbonate - Fosrenol(r) - tablets is on the cards, thanks to collaboration between the Mumbai-based pharma biggie, Lupin, and the Hyderabad-based integrated pharmaceutical and bulk chemicals' manufacturer, Natco Pharma.

Talking about the Lupin-Natco collaboration for Fosrenol(r), a Natco spokesperson said that the accord will help Natco battle a patent lawsuit recently filed by the Fosrenol(r) innovator - the UK-based firm, Shire Plc.

According to Lupin and Natco, both the Indian companies are amongst the first ones to file for an abbreviated new drug application (ANDA), which would provide them 180-day exclusivity for selling the generic versions of Fosrenol(r) tablets, which are used for the treatment of chronic kidney ailments.

Even though the chief market for Fosrenol(r) is India, the drug reportedly achieved sales worth $108 million the US in December 2008.

Highlighting the overall benefits of the Lupin-Natco agreement, Nilesh Gupta - the Lupin group President and Executive Director - said: "The alliance creates synergies that will enable portfolio expansion and contribute to consolidating our presence in the US markets. Lupin's proven IP management capabilities, marketing reach and expertise coupled with Natco's solid development and manufacturing abilities make for a great combination!"